Fingerprint
Dive into the research topics of 'Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically